Background: We conducted a phase II study to assess the efficacy and tolerability of docetaxel and epirubicin as salvage chemotherapy in advanced/metastatic gastric cancer patients with documented progression after 5-fluorouracil/platinum-based combination chemotherapy. Methods: Docetaxel 75 mg/m2 and epirubicin 50 mg/m2 were administered on days 1 and 2, respectively, every 3 weeks. Treatment continued until progression of disease or until a life-threatening adverse event occurred. The primary objectives of this study were to evaluate the safety profile and response rate to this treatment regimen. Results: Thirty-four patients were enrolled in the study. Twenty-six patients had locally advanced or metastatic disease at the time of diagnosis, and 8 patients had recurrent disease after surgical resection of the primary tumor. A total of 157 chemotherapy cycles were administered. Seven (21.8%) patients had a partial response and 12 (37.5%) patients had stable disease. The median time to progression and overall survival were 4.1 and 13.4 months, respectively. Grade III/IV hematologic toxicities included neutropenia in 16 patients (47%) and febrile neutropenia in 8 patients (24%). Nonhematologic toxicities were rare. Conclusion: A combination of chemotherapy with docetaxel and epirubicin showed moderate activity as salvage treatment in advanced/metastatic gastric cancer, especially in patients who had responded to prior chemotherapy.

Keywords:
Gastric cancer, Docetaxel chemotherapy
1.
Jernal A, Thomas A, Murray T, Thun M: Cancer statistics 2002. CA Cancer J Clin 2002;52:23–47.
2.
Bae JM, Won YJ, Jung KW, Park JG: Annual report of the Korean central cancer registry program 2000. Cancer Res Treat 2002;34:77–83.
3.
Alberts SR, Cervantes A, van de Velde CJH: Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003;14(suppl 2):ii31–ii36.
4.
Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PD, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163–168.
5.
Wagner AD, Grothe W, Behl S, Kleber G, Grothey A, Haerting J, Fleig WE: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2005;18:CD004064.
6.
Murad AM, Skare NG, Vinholes J, Lago S, Pecego R: Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil (DEF) in the treatment of advanced gastric cancer: a novel, safe, and active regimen. Gastric Cancer 2006;9:99–105.
7.
Roth AD, Ajani JA: Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 2003;14(suppl 2):ii41–ii44.
8.
Ajani JA: Evolving chemotherapy for advanced gastric cancer. Oncologist 2005;10(suppl 3):49–58.
9.
Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR, Ward C, Iveson T, Nicolson M, Hickish T, Hill M, Oates J: Report of two protocol planned interim analyses in a randomized multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005;92:1976–1983.
10.
Budman D, Calabro A, Kreis W: Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 2002;13:1011–1016.
11.
Budman D, Calabro A: In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines. Breast Cancer Res Treat 2002;74:41–46.
12.
Polyzos A, Tsavaris N, Kosmas C, Gogas H, Vadiaka M, Markopoulos C, Giannopoulos A, Kalahanis N, Stamatiadis D, Kouraklis G, Karatzas G, Liapis C, Syrigos K: Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer. Anticancer Res 2003;23:2917–2923.
13.
Pagani O, Sessa C, Martinelli G, Crivellari D, Buonadonna A, Thurlimann B, Hess D, Borner M, Bauer J, Zampino G, Zimatore M, Graffeo R, Riva A, Goldhirsch A: Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Ann Oncol 1999;10:539–545.
14.
Kouroussis C, Xydakis E, Potamianou A, Giannakakis T, Kakolyris S, Agelaki S, Sara E, Malamos N, Alexopoulos A, Mavroudis D, Samonis G, Papadouris S, Georgoulias V, Panagos G, for the Greek Breast Cancer Cooperative Group (GBCCG): Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. Ann Oncol 1999;10:547–552.
15.
Venturini M, Michelotti A, Papaldo P, Del Mastro L, Bergaglio M, Lionetto R, Lunardi G, Sguotti C, Frevola L, Donati S, Rosso R, Cognetti F: Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients. Ann Oncol 2001;12:1097–1106.
16.
National Comprehensive Cancer Network: NCCN practice guidelines for upper gastrointestinal carcinomas. Oncology (Huntingt) 1998;12:179–223.
17.
Ajani JA: Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol 2000;18:4001–4002.
18.
Wilson D, Hiller L, Geh JI: Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol 2005;17:81–90.
19.
Vanhoefer U, Wilke H, Harstrick A, Achterrath W, Preusser P, Stahl M, Clemens MR, Thiel E, Flasshove M, Fink U, Trenn G, Seeber S: Phase II study of docetaxel as second-line chemotherapy in metastatic gastric cancer (abstract 1163). Proc Am Soc Clin Oncol 1999;18.
20.
Giuliani F, Gebbia V, De Vita F, Maiello E, Di Bisceglie M, Catalano G, Gebbia N, Colucci G: Docetaxel (taxotere) as salvage chemotherapy in patients with advanced gastric cancer. A phase II study of the Southern Italian Oncology Group (GOIM) (abstract 296P). Ann Oncol 2000;11(suppl 4):67.
21.
Andre T, Louvet C, Ychou M, Gamelin E, Mousseau M, Carola E, Assadourian S, Gramont AD: Docetaxel-epirubicin as second-line treatment for patients with advanced gastric cancer (abstract 1062). Proc Am Soc Clin Oncol 1999;18.
22.
Nguyen S, Rebischung C, Van Ongeval J, Flesch M, Bennamoun M, Andre T, Ychou M, Gamelin E, Carola E, Louvet C: Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment. Bull Cancer 2006;93:E1–E6.
23.
Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y: Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 2006;9:14–18.
24.
Baek JH, Kim JG, Sohn SK, Kim DH, Lee KB, Song HS, Kwon KY, Do YR, Ryoo HM, Bae SH, Park KU, Kim MK, Lee KH, Hyun MS, Chung HY, Yu WS: Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study. J Korean Med Sci 2005;20:966–970.
25.
Kunisaki C, Imada T, Yamada R, Hatori S, Ono H, Otsuka Y, Matsuda G, Nomura M, Akiyama H, Kubo A, Shimada H: Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma. Anticancer Res 2005;25:2973–2978.
26.
Park SH, Choi EY, Bang SM, Cho EK, Lee JH, Shin DB, Lee WK, Chung M: Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. Anticancer Drugs 2005;16:621–625.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.